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Abstract
Grafting bone defects or atrophic non-unions with 
mesenchymal stromal cells (MSCs)-based grafts is 
not yet successful. MSC-based grafts typically use 
undifferentiated or osteogenically differentiated MSCs and 
regenerate bone through intramembranous ossification. 
Endochondral ossification might be more potent but 
requires chondrogenic differentiation of MSCs. Here, 
we determined if chondrogenically differentiated MSC 
(ch-MSC) pellets could induce bone regeneration in an 
orthotopic environment through endochondral ossification. 
Undifferentiated MSC pellets (ud-MSC) and ch-MSC 
pellets were generated from MSCs of human donors 
cultured on chondrogenic medium for respectively 3 
(ud-MSC) and 21 (ch-MSC) days. A 6 mm femoral bone 
defect was made and stabilised with an internal plate in 
27 athymic rats. Defects were left empty for 6 weeks to 
develop an atrophic non-union before they were grafted 
with ch-MSC pellets or ud-MSC pellets. Micro-CT scans 
made 4 and 8 weeks after grafting showed that ch-MSC 
pellets resulted in significantly more bone than ud-MSC 
pellets. This regenerated bone could completely bridge the 
defect, but the amount of bone regeneration was donor-
dependent. Histology after 7 and 14 days showed slowly 
mineralising pellets containing hypertrophic chondrocytes, 
as well as TRAP-positive and CD34-positive cells around 
the ch-MSC pellets, indicating osteoclastic resorption and 
vascularisation typical for endochondral ossification. In 
conclusion, grafting critical femoral bone defects with 
chondrogenically differentiated MSC pellets led to rapid 
and pronounced bone regeneration through endochondral 
ossification and may therefore be a more successful MSC-
based graft to repair large bone defects or atrophic non-
unions. But, since bone regeneration was donor-depend, the 
generation of potent chondrogenically differentiated MSC 
pellets for each single donor needs to be established first.
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Bone development and fracture repair occur through 
intramembranous or endochondral ossification (Shapiro, 
2008). In intramembranous ossification, mesenchymal 
stromal cells (MSCs) differentiate directly into osteoblasts 
that form bone. In endochondral ossification, MSCs 
differentiate into chondrocytes, which form a cartilage 
template (Kronenberg, 2003). Chondrocytes within this 
template become hypertrophic and start to secrete cytokines 
such as vascular endothelial growth factor (VEGF), and 
enzymes like alkaline phosphatase (ALP) and proteases 
(e.g., matrix metalloproteinases (MMPs)). Together, these 
factors stimulate vascularisation and mineralisation of 
the cartilage template, which is subsequently resorbed by 
attracted osteoclasts and replaced by bone. Which type 
of ossification predominantly occurs in fracture repair is 
highly dependent on biomechanical conditions. Absence 
of motion results in intramembranous ossification, 
although this is only capable of bridging small gaps (200-
500 µm), whereas micromotions stimulate endochondral 
ossification, through which larger fracture gaps are 
regenerated (Carter et al., 1998).
 Despite modern treatment, fracture repair remains 
insufficient or impaired in 10 % of all fractures resulting 
in non-unions or persistent bone defects (Einhorn, 1995). 
Bone defects and atrophic non-unions can be treated with 
bone grafts, for which the current gold standard material is 
autologous bone (Cypher and Grossman, 1996). However, 
harvesting autologous bone results in a high morbidity 
rate (10-40 %) (Banwart et al., 1995; Dimitriou et al., 
2011), and the amount that can be harvested is limited. 
These disadvantages fuelled the development of bone graft 
substitutes. Ideally a bone graft substitute should consist 
of a biodegradable material that offers direct mechanical 
support and functions as an osteoconductive scaffold that 
facilitates bone regeneration. Also the material should 
provide osteogenic and angiogenic stimuli to enhance 
bone regeneration and vascularisation (Giannoudis et 
al., 2007). Bone graft substitutes currently available for 
clinical use mainly rely on osteoconductive properties 
(Van der Stok et al., 2011). Only in a small case-series, 
an osteoconductive bone substitute has been combined 
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with MSCs to graft bone defects (Quarto et al., 2001). But 
so far the clinical success of MSC-based grafts remains 
disappointing (Steinert et al., 2012). This may be because 
those MSC-based grafts contained undifferentiated or 
osteogenically differentiated MSCs and thus stimulated 
intramembranous ossification. Differentiation of MSCs 
towards chondrocytes, and thereby aiming to stimulate 
endochondral ossification, may be a more successful 
strategy (Gawlitta et al., 2010).
 Chondrogenically differentiated embryonic stem 
cells (Jukes et al., 2008), embryonic chondrocytes 
(Oliveira et al., 2009a) or MSCs (Farrell et al., 2009) 
can undergo hypertrophy and secrete factors similar to 
those normally secreted by hypertrophic chondrocytes 
during endochondral ossification (e.g., VEGF, MMP-13, 
and ALP). In vivo, chondrogenically differentiated MSCs 
can form bone through endochondral ossification after 
ectopic implantation in mice (Jukes et al., 2008; Oliveira 
et al., 2009b; Scotti et al., 2010; Farrell et al., 2011). But 
ectopic implantation does not fully reflect the complex 
environment of a bone defect or an atrophic non-union. 
In an orthotopic environment, bone regeneration starts 
with a low-grade inflammatory phase (Claes et al., 2012), 
under low-oxygen tensions (Brighton and Krebs, 1972), 
and is continuously exposed to biomechanical stimuli. All 
these factors are known to affect MSCs differentiation and 
survival (Lacroix and Prendergast, 2002). In this study, 
we therefore made critical femoral bone defects in rats, 
and left these defects untreated for 6 weeks to establish 
an atrophic non-union. Subsequently the defects were 
grafted with chondrogenically differentiated MSC pellets 
to determine whether chondrogenically differentiated MSC 
pellets remain capable of endochondral ossification in this 
orthotopic environment. We hypothesised that grafting 
with chondrogenically differentiated MSC pellets enhances 
bone regeneration and used grafting with undifferentiated 
MSC pellets as a control. Bone regeneration was evaluated 
with the use of micro-CT scanning, histology and 
immunohistochemistry.
Materials and Methods
Isolation and expansion of human bone marrow cells
Human bone marrow derived MSCs of three donors 
(donor 1: female, 75 years, donor 2: female, 77 years, 
donor 3: female, 55 years) were obtained during total 
hip arthroplasty after informed consent and approval 
of the local medical ethical committee (METC 2004-
142). Bone marrow aspirates were taken from the great 
trochanter. Heparinised aspirates were seeded at a density 
of 30-100 x 106 nucleated cells per T175 flask. After 24 h, 
non-adherent cells and cell debris were washed out. MSCs 
were further expanded in low-glucose Dulbecco’s modified 
Eagle medium (DMEM) with 10 % foetal calf serum 
(Lonza, Basel, Switzerland) supplemented with 50 µg/mL 
of gentamicin, 1.5 µg/mL of Fungizone (all Invitrogen/Life 
Technologies, Carlsbad, CA, USA), 0.1 mM of L-ascorbic 
acid 2-phosphate and 1 ng/mL of fibroblast growth 
factor-2 (Instruchemie, Delfzijl, The Netherlands). Cells 
were cultured at 37 °C under humidified conditions and 
5 % carbon dioxide (CO2). Medium was changed twice a 
week. When cultured cells neared confluence, they were 
trypsinised using 0.05 % trypsin and replated at a density 
of 2,000 cells/cm2. Cells from the third passage were used 
for pellet cultures.
Culturing of chondrogenically differentiated MSC 
pellets and undifferentiated MSC pellets
After detachment of cells with 0.05 % trypsin, 0.5 mL 
of medium, containing 200,000 cells, was put in a 
polypropylene tube. Tubes were centrifuged for 8 min 
at 120 g. Undifferentiated MSC (ud-MSC) pellets and 
chondrogenically differentiated MSC (ch-MSC) pellets 
were maintained for respectively 3 and 21 days on 
high-glucose DMEM, supplemented with 50 µg/mL of 
gentamicin, 1.5 µg/mL of Fungizone (Invitrogen), 0.1 mM 
L-ascorbic acid 2-phosphate, 40 µg/mL L-proline, 1 mM 
of sodium pyruvate (Sigma-Aldrich, St. Louis, MO, USA), 
1:100 insulin-transferrin-selenium (ITS) (BD Biosciences, 
East Rutherford, NJ, USA), 10 ng/mL of transforming 
growth factor (TGF)-1 (R&D Systems, Minneapolis, MN, 
USA), and 100 nM of dexamethasone (Sigma-Aldrich). 
After maintaining ud-MSC pellets and ch-MSC pellets 
for respectively 3 and 21 days, they were directly used 
for implantation.
Animal experiment
Twenty-seven skeletally mature male RNU rats (Charles 
River, Wilmington, MA, USA) were used as experimental 
animals (361 ±36 g body weight). When the animals were 
16 weeks old a critical femoral bone defect was made by 
removal of 6 mm cortical bone, while stabilised with an 
internal fixation plate. Six weeks later, in a second surgical 
procedure, bone defects were grafted with ch-MSC pellets 
(n = 15) or ud-MSC pellets (n = 12). The Animal Ethics 
Committee of the Erasmus University approved the study 
(ECM 1493) and Dutch guidelines for the care and use of 
laboratory animals were applied.
Surgical procedures
Prior to surgery, prophylactic antibiotics (enrofloxacin, 
5 mg/kg body weight) and pain medication (buprenorphine, 
0.05 mg/kg body weight) were administered. Surgical 
procedures were performed aseptically under general 
anaesthesia (1-3.5 % isoflurane).
 During the first surgical procedure, a critical femoral 
bone defect was made as follows: the right femur was 
exposed through a lateral skin incision and division of 
underlying fascia. A 23 mm long polyetheretherketone 
(PEEK) plate was fixed to the anterolateral plane of the 
femur using three proximal and three distal screws (RatFix, 
RISystem, Davos-Platz, Switzerland). Periosteum was 
removed over approximately 8 mm of the mid-diaphyseal 
region before removal of 6 mm cortical bone. Bone was 
removed with a tailor-made saw guide and a wire. Fascia 
and skin were sutured in layers using Vicryl 5-0. Antibiotic 
medication was continued for 2 days post-surgery, and pain 
medication was continued for 3 days.
 During the second surgical procedure, 6 weeks later, 
critical bone defects were grafted with ch-MSC or ud-
MSC pellets as follows: the right femur was again exposed 
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through a lateral skin incision and division of underlying 
fascia. After full exposure of the femur, none of defects had 
bridged and the defect was filled with fibrous tissue (Fig. 1 
a and b). After debridement and trimming of bone edges at 
proximal and distal side, defects were grafted with six ch-
MSC or ud-MSC pellets (Fig. 1c). Pellets were contained 
inside the defect by closure through intramuscular sutures 
(Vycril 5-0). Subsequently fascia and skin were sutured. 
Antibiotic medication was continued for two days post-
surgery, pain medication was continued for three days. 
Rats were killed by an overdose pentobarbital.
Micro-CT evaluation
Bone regeneration was followed longitudinally by in vivo 
micro-CT scans, acquired under general anaesthesia (1-
3.5 % isoflurane). A timeline was acquired by scanning 
one rat of ch-MSC-group and one rat of ud-MSC-group 
every week, while the remaining rats (n = 8 per group) 
only underwent scans at 4 and 8 weeks to quantify bone 
regeneration. Micro-CT scans were made with a SkyScan 
1176 scanner (Bruker micro-CT; www.bruker.com) using 
a 35 µm-resolution protocol (65 kV, 385 µA current, 
1 mm Al filter, and 0.5° rotation step, resulting in a 7 min 
scan). CT images were reconstructed using volumetric 
reconstruction software NRecon version 1.5 (Bruker 
micro-CT). Bone volume (BV) was quantified within the 
6 mm defect after segmentation of calcified tissue from 
non-calcified tissue using a global threshold. This global 
threshold was determined based on visual inspection and 
was kept constant for all scans.
Histological and immunohistochemical evaluation
Histology and immunohistochemistry was done on ch-
MSC and ud-MSC pellets cultured in vitro (n = 3 per 
donor) and on grafted femoral bone defects after 3, 7 
and 14 days (n = 2 ch-MSC-group, n = 1 ud-MSC-group 
at each time-point) and after 8 weeks (n = 8 per group). 
Pellets and grafted femora were fixed in 10 % neutral 
buffered formalin solution for 2 days. Grafted femora 
were decalcified in 10 % EDTA in phosphate buffered 
saline (PBS) solution (pH 7.4) for 6 weeks. Finally, all 
specimens were dehydrated in graded ethanol solutions 
(70-100 %) and xylene before embedding in paraffin. 
6 µm paraffin sections were cut with a microtome 
(Leica, Solms, Germany; RM2135). Pellets were stained 
with haematoxylin-eosin (H&E) and thionin, and 
immunostained for collagen II, collagen X and vascular 
endothelial growth factor (VEGF). Grafted femurs were 
stained with H&E, thionin, and tartrate-resistant acid 
phosphatase (TRAP), and immunostained for collagen II 
and CD34.
 Collagen II is a marker for chondrogenic differentiation 
and collagen X is a marker for hypertrophy. Antigen 
retrieval for collagen II was performed through 30 min 
incubation of sections with 0.1 % pronase in PBS, while 
antigen retrieval for collagen X required 0.1 % pepsin in 
0.5 M acetic acid (pH 2.0) for 2 h. Both collagen II and 
collagen X stainings continued by incubation with 1 % 
hyaluronidase in PBS for 30 min. Non-specific binding sites 
were blocked with 10 % goat serum in PBS and sections 
were stained overnight with primary antibodies against 
collagen II (II/II6B3 antibody, 1:100, Developmental 
Fig. 1. Critical femur defect with PEEK plate fixation (a) and transversal micro-CT images directly after removal of 
6 mm cortical bone and after 6 weeks. Fibrous tissue that was removed from the defect (b) before 6 ch-MSC pellets 
were used to graft the defect (c).
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Studies Hybridoma Bank, Iowa City, IA, USA under 
contract N01-HD-6-2915 from the National Institute of 
Child Health and Human Development) or collagen X 
(1:30, X53, Quartett, Berlin, Germany). To allow the use of 
monoclonal mouse antibodies on human constructs grafted 
in a nude rat, we used a method described by Hierck et al. 
(Hierck et al., 1994). An alkaline-phosphatase-conjugated 
secondary antibody was used followed by incubation with 
Neu Fuchsin substrate (Chroma, Rockingham, VT, USA) 
to demonstrate alkaline-phosphatase activity with a red 
staining. The positive control for collagen II was bovine 
cartilage, and for collagen X we used known hypertrophic 
pellets. An isotype control was taken along as negative 
control for both stainings.
 VEGF is an angiogenic growth factor, and after 
microwave treatment in 10 mM citric acid buffer pH 6.0, 
sections were blocked with 5 % bovine serum albumin 
(BSA) in PBS for 10 min and incubated overnight at 4 °C 
with VEGF antibody (sc-152, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) diluted in 5 % bovine serum 
albumin (BSA) in PBS. Secondary antibodies against 
human IgG were conjugated with peroxidase (Dako, 
Glostrup, Denmark). CD34 is an endothelial cell marker 
indicating vessel-structures, and antigen retrieval for CD34 
was performed through 30 min incubation with 0.1 % 
trypsin (Sigma-Aldrich). Non-specific binding sites were 
blocked with 10 % NGS and sections were incubated 
with primary antibody against rat CD34 (R&D Systems). 
A biotinylated rabbit antibody followed by alkaline 
phosphatase conjugated streptavidin and incubation with 
Neu Fuchsin substrate (Chroma) was used to visualise 
positive staining. Slides were counterstained with 
haematoxylin. The positive control for VEGF was human 
skin and an isotype control was taken along as negative 
control.
Release of angiogenic cytokines
Secretion of angiogenic cytokines was measured in culture 
medium taken of the ch-MSC and ud-MSC pellets at the 
day of implantation using a human cytokine angiogenic 
multiplex chemiluminescent ELISA (Cat. No. 150251HU, 
Quansys Biosciences, Logan, UT, USA). This angiogenic 
multiplex measures angiotensin II (Ang-2), fibroblast 
growth factor-2 (FGF-2), hepatocyte growth factor (HGF), 
interleukin-8 (IL-8), platelet derived growth factor-BB 
(PDGF-BB), tissue inhibitor of metalloproteinase 1 and 
2 (TIMP-1 and TIMP-2), tumour necrosis factor- (TNF), 
and VEGF. Multiplex chemiluminescent ELISA kits were 
performed according to the manufacturer’s instructions 
and the plate was imaged using Kodak Digital Science™ 
Image Station 440CF system (NEN Life Science Products, 
Boston, MA, USA). Angiogenic cytokine concentrations 
were calculated using Q-view software® (Quansys 
Biosciences).
Statistics
The design of this study was aimed to find at least a 
duplication in the BV formed within the 6 mm defect. 
The standard deviation of BV formed was estimated to be 
~50 % based on previous work (Chatterjea et al., 2013; 
Van der Stok et al., 2013a; Van der Stok et al., 2013b). A 
simple power calculation using a Students’ t-test with a 
β-value of 0.8 indicates that both groups should consist of 
a minimum of 5 rats. The final decision to use 8 rats per 
group accounted for loss of animals (e.g., failure of fixation 
material to stabilise the defect) or loss of donors (e.g., 
insufficient of unsuccessful chondrogenic differentiation 
of MSCs). Statistical analyses were performed using 
SPSS Statistics 20.0 (SPSS Inc, Chicago, IL, USA). The 
data are presented as means with standard deviation (SD). 
Mixed models analysis was used to test for statistical 
differences between ch-MSC-group and ud-MSC-group, 
while correcting for donor effect using MSC donor as 
random factor. A p-value less than 0.05 was considered a 
statistically significant difference.
Results
Culturing and characterisation of ch-MSC or ud-
MSC pellets
Ch-MSC pellets were 2-3 mm in diameter and contained 
hypertrophic chondrocytes surrounded by an extensive 
extracellular matrix (Fig. 2, a1). This extracellular matrix 
contained high levels of GAGs, collagen II and collagen 
X, indicated by thionin staining and collagen II and X 
immunostaining (Fig. 2, b1-d1 respectively). VEGF was 
mainly positive in and around the cells, but not in the 
extracellular matrix (Fig. 2, e1). Ud-MSC pellets were 
about 1 mm in diameter and contained densely packed 
cells without substantial extracellular matrix (Fig. 2, a2). 
Cells had not undergone chondrogenic differentiation as 
no GAGs, nor collagen II or collagen X were observed on 
thionin staining and collagen II or X immunostaining (Fig. 
2, b2-d2 respectively). VEGF was also produced by ud-
MSC pellets and was mainly found in and around the cells 
(Fig. 2, e2). Per donor, approximately 180-200 pellets were 
cultured from passage three human derived MSCs, which 
can theoretically result in 0.8-2.7 cm3 of ch-MSC pellets.
Micro-CT evaluation 
Two weeks after grafting the defects, ch-MSC pellets 
started to mineralise whereas no mineralisation of ud-MSC 
pellets was observed (Fig. 3). Mineralisation of ch-MSC 
pellets started around the pellets and progressed towards 
the centre. Mineralised pellets also integrated with bone 
formed at the cortical bone edges. In one defect grafted with 
ch-MSC pellets of donor 1, bone formation was capable 
of completely bridging this defect within 4 weeks (Fig. 4). 
Once this defect was bridged, the original bone architecture 
was restored through bone remodelling. In other defects 
grafted with ch-MSC pellets of donor 1 or donor 3, a 
minimal gap (< 0.5 mm) remained visible after 8 weeks 
(Fig. 5a). Defects grafted with ch-MSC pellets of donor 2 
or with ud-MSC pellets showed little bone formation and 
defects were not bridged.
 Bone quantification showed that grafting bone defects 
with ch-MSC pellets led to significantly more bone 
regeneration than grafting with ud-MSC pellets (p = 0.041) 
(Fig. 5b). After 4 and 8 weeks, average BV of all defects 
grafted with ch-MSC pellets was almost twice as much 
as defects grafted with ud-MSC pellets (4 weeks 33.1 
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±18.8 mm3 versus 17.8 ±8.6 mm3, 8 weeks 41.8 ±24.7 mm3 
versus 24.2 ±12.2 mm3). This effect was donor dependent, 
ch-MSC pellets of donor 1 and 3 resulted in BVs of 39.6 
±9.7 mm3 (donor 1) and 53.8 ±10.7 mm3 (donor 3) after 4 
weeks and 53.8 ±19.5 mm3 (donor 1) and 63.2 ±0.8 mm3 
(donor 3) after 8 weeks. But grafting defects with ch-MSC 
pellets of donor 2 only resulted in 13.3 ±12.4 mm3 BV after 
8 weeks, which was not more than grafting with ud-MSC 
pellets (25.1 ±6.6 mm3). Compared to donor 2, ud-MSC 
pellets of donor 1 and 3 resulted in similar BVs and were 
36.7 ±5.2 mm3 and 13.8 ±0.1 mm3 respectively.
Histological evaluation
Grafted ch-MSC pellets were clearly visible in the defect 
after 7 and 14 days (Fig. 6, a1-2). They formed a cartilage 
template that bridged the defect. After 7 days, ch-MSC 
pellets were surrounded by a number of cell layers (Fig. 
6, b1, c1, and d1). At this time, some vessel-forming 
activity was detected around the ch-MSC pellets (Fig. 6, 
f1: arrows), without substantial osteoclast activity (Fig. 6, 
e1). After 14 days, the cartilage template was reduced in 
size (Fig. 6, b1, c1, and d1) and more osteoclast activity 
was observed along the edges of the remaining ch-MSC 
pellets (Fig. 6, e2: arrows). Areas of osteoclast activity were 
Fig. 2. Histology of ch-MSC pellets (a1) and ud-MSC pellets (a2): ch-MSC pellets were bigger and generated more 
extracellular matrix than ud-MSC pellets, bar indicates 500 µm. Detailed views showed that the extracellular matrix 
of ch-MSC pellets is rich of GAGs (b1), collagen II (c1) and collagen X (d1), indicating that ch-MSC pellets had 
undergone hypertrophic chondrogenic differentiation. VEGF was predominantly found in and around the cells (e1). 
Ud-MSC pellets generated little to none extracellular matrix and had not undergone chondrogenic differentiation 
(b2, c2, and d2). VEGF was found throughout the pellets (e2). Bar indicates 50 µm.
Fig. 3. Repeated micro-CT scans of defects grafted with ch-MSC pellets or ud-MSC pellets of donor 1. Ch-MSC 
pellets mineralise after 2 weeks, and integrate with adjacent cortical host bone at 4 weeks. Ud-MSC pellets did not 
show mineralisation throughout the 8 week follow-up. Bar indicates 1 mm.
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Fig. 4. Remodelling of mineralised pellets (4 weeks) 
restoring the original cortex and medullary canal (8 
weeks) of the defect grafted with ch-MSC pellets of 
donor 1 that showed complete bridging. Black arrow 
heads depict border of ch-MSC pellets, ‘c’ indicates 
the newly formed cortex and ‘m’ indicates the ongoing 
restoration of the medullary canal. Bar indicates 1 mm.
Fig. 5. Micro-CT images of defects grafted with ch-MSC or ud-MSC pellets of all three donors after 8 weeks (a). 
Defects grafted with ch-MSC pellets of donor 1 and 3 show more bone formation than grafting with ud-MCS pellets, 
but defects grafted with ch-MSC pellets of donor 2 showed did not show more bone formation than defects grafted 
ud-MSC pellets of donor 2. Bar indicates 1 mm. Bone volumes measured in 6 mm bone defect after 4 weeks and 8 
weeks (b).
Fig. 6. Histology of the 6 mm bone defect grafted with ch-MSC pellets after 7 and 14 days (a1-2), bar indicates 
500 µm. Detailed views show that ch-MSC pellets were surrounded by a number of cell layers (b1-2) and that the 
extracellular matrix remained rich of GAGs (c1-2) and collagen II (d1-2). Osteoclast activity was observed after 14 
days (e1-2: arrows) and some vessel-forming activity was found in the surrounding host tissue (f1-2: arrows), bar 
indicates 250 µm.
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Fig. 7. Histology of the 6 mm bone defect grafted with ud-MSC pellets after 7 and 14 days (a1-2), bar indicates 
500 µm. Detailed views show that ud-MSC pellets were surrounded by small round cells (b1-2). Ud-MSC pellets 
did not form an extracellular matrix containing GAGs (c1-2) or collagen II (d1-2), indicating that ud-MSC pellets 
had not undergone chondrogenic differentiation. No osteoclast activity was observed (e1-2), but widespread vessel-
forming activity was found in the surrounding host tissue (f1-2: arrows), bar indicates 250 µm.
Fig. 8. Histology of the 6 mm 
bone defect grafted with ch-MSC 
pellets or ud-MSC pellets after 8 
weeks stained with respectively 
H&E (a1-2) or thionin (b1-2) 
and corresponding micro-CT 
images (c1-2). Bone tissue is 
indicated with ‘b’, cartilage 
tissue is indicated with ‘c’ and 
fibrous tissue is indicated with 
‘f’. Asterisk marks area showed 
in more detail in Fig. 9. Bar 
indicates 1 mm.
accompanied by vessel-forming activity and vessel-like 
structures (Fig. 6, f2: arrows). Grafted ud-MSC pellets also 
remained visible up to 14 days, but did not form a cartilage 
template inside the defect (Fig. 7, a1-2). After 7 and 14 
days, ud-MSC pellets had not undergone chondrogenic 
differentiation (Fig. 7, b1-2, c1-2 and d1-2) and were 
surrounded by a high number of small round cells. After 7 
and 14 days, there was no osteoclast activity (Fig. 7, e1-2) 
but in the surrounding tissue substantial vessel-forming 
activity was observed (Fig. 7, f1-2: arrows).
 After 8 weeks, grafted ch-MSC pellets were almost 
completely resorbed and replaced by bone (Fig. 8, a1 and 
b1). Bone close to the remaining gap consisted of woven 
bone and some small areas of vessel-forming activity were 
found in the proximity of the fracture gap (Fig. 9, a1 and 
c1: arrows), while the remaining gap consisted of cartilage 
tissue (Fig 9, b1). In defects grafted with ud-MSC pellets, 
no cartilage tissue nor remnants of ud-MSC pellets were 
observed (Fig. 8, a2 and b2), and the remaining gap was 
filled with fibrous tissue (Fig. 9, a2 and b2). Within this 
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fibrous tissue, vessel-forming activity was clearly observed 
(Fig. 9, c2: arrows). In both groups, bone observed on 
histology showed a good correlation with bone seen on 
corresponding micro-CT images (Fig. 8, c1-2).
 Ch-MSC pellets of donor 2, which did not stimulate 
bone regeneration (Fig. 5), were smaller in size (~0.5 mm) 
and contained more closely packed cells than ch-MSC 
pellets of donor 1 (Fig. 10, a1-2) or donor 3. Cell nuclei 
of ch-MSC pellets of donor 2 seemed viable (Fig. 10, 
c2), but the cell nuclei of ch-MSC pellets of donor 1 and 
donor 3 were smaller or had shrunk and more empty cell 
lacunae were observed throughout the extracellular matrix 
(Fig. 10, c1). Ch-MSC pellets of donor 1 and 2 had both 
undergone chondrogenic differentiation and consisted of 
hypertrophic chondrocytes (Fig. 10, d1-2 and e1-2), but 
the extracellular matrix of ch-MSC pellets from donor 2 
Fig. 9. Detailed views of the 6 mm bone defect grafted with ch-MSC pellets or ud-MSC pellets after 8 weeks, stained 
with respectively H&E (a1-2), thionin (b1-2) and CD34 immunostaining (c1-2). Bone tissue is indicated with ‘b’, 
cartilage tissue is indicated with ‘c’ and fibrous tissue is indicated with ‘f’. Arrows indicate vessel forming activity. 
Bar indicates 250 µm.
Fig. 10. Histology of ch-MSC pellets of donor 1 and 2 showing that ch-MSC pellets of donor 1 were bigger than 
ch-MSC pellets of donor 2 (a1-2). Bar indicates 500 µm. Detailed views showed that ch-MSC pellets of donor 1 
formed a more structured extracellular matrix (b1-2 and c1-2), although the extracellular matrix of both donors 
contained collagen II (d1-2) and collagen X (e1-2), indicating that MSC of both donors had undergone hypertrophic 
chondrogenic differentiation. Bar indicates 50 µm.
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Fig. 11. Angiogenic cytokines released from ch-MSC and ud-HTC pellets in culture medium retrieved before grafting 
the bone defects.
appeared less structured than the extracellular matrix of 
ch-MSC pellets from donor 1 (Fig. 10, b1-2).
Release of angiogenic cytokines
Release of hTIMP-1 and PDGF-BB is not shown because 
release of hTIMP-1 exceeded the upper quantification limit 
(3000 pg/mL) and release of PDGF-BB did not exceed the 
lower quantification limit (1000 pg/mL) of the assay. Ch-
MSC pellets of all three donors released hVEGF, hTIMP-2, 
hAng-2, hTNFa, hFGF, and hHGF (Fig. 11). Cytokine 
release of ch-MSC pellets of donor 2 was not different from 
the cytokine release of the ch-MSC pellets of donor 1 and 
3. Compared to ud-MSC pellets, less VEGF was released 
by ch-MSC pellets and no hIL-8 release was observed.
Discussion
Grafting bone defects and atrophic non-unions with MSC-
based grafts is believed to hold great potential (Huey et al., 
2012), but so far clinical results are rather disappointing 
(Steinert et al., 2012). Therefore, instead of stimulating 
intramembranous ossification with undifferentiated 
or osteogenically differentiated MSCs, some papers 
advocate to stimulate endochondral ossification with 
chondrogenically differentiated MSCs (Farrell et al., 2009; 
Oliveira et al., 2009b; Scotti et al., 2010). In our study, 
grafting of critical femoral bone defects that were left 
untreated for 6 weeks with chondrogenically differentiated 
MSC pellets was found to result in significantly more 
bone than grafting with undifferentiated MSC pellets 
(Figs. 3 and 5) and we showed that this bone was formed 
through endochondral ossification (Fig. 6). Grafting with 
chondrogenically differentiated MSC pellets can result 
in bone regeneration capable of completely bridging the 
defect (Fig. 4). However, the effect of chondrogenically 
differentiated MSC pellets is donor-depend (Fig. 5).
 The complex orthotopic environments that can be 
encountered during insufficient or impaired fracture 
repair (Garcia et al., 2013) were simulated using a critical 
femoral bone defect model that was grafted after 6 
weeks. During the first 6 weeks, untreated defects formed 
an atrophic non-union and the remaining fracture gap 
was filled with fibrous tissue (Fig. 1c). Grafting these 
defects with chondrogenically differentiated MSC pellets 
resulted in large amounts of bone formation through 
endochondral ossification (Fig. 5b). Although extensive 
bone regeneration was observed in defects grafted with 
chondrogenically differentiated MSC pellets of donor 1 and 
3, only one defect was completely bridged after 8 weeks 
(Fig. 4). The inability to bridge the other defect is may be 
explained by a suboptimal method of fixation, because 
the micro-CT images of these defects show the formation 
of a hypertrophic non-union with a typical horse-shoe or 
elephant-foot configuration (Figs. 5 and 8) (Naimark et al., 
1981), and the remaining fracture gap contained cartilage 
tissue (Fig. 8 and 9). Although a longer follow-up might 
have resulted in union, hypertrophic non-unions are usually 
well treated by providing increased stability over the non-
union (Megas, 2005).
 Similar to previous ectopic implantations (Jukes et al., 
2008; Oliveira et al., 2009b; Scotti et al., 2010; Farrell 
et al., 2011), we used immunocompromised animals to 
avoid host-versus-graft reactions against human MSCs. 
This raised the relevant question whether chondrogenically 
differentiated MSC pellets remain capable of initiating 
endochondral ossification in an immunocompetent host. 
Chondrogenically differentiated MSCs of rat origin have 
shown to remain capable of initiating endochondral 
ossification when implanted in immunocompetent rats 
(Farrell et al., 2006; Farrell et al., 2011). The use of 
rat MSCs makes it also possible to gain more insight 
in the influence of a specific immune response of the 
host to implanted chondrogenically differentiated MSC 
pellets. Specific immune responses may be the driving 
factor in the bone regeneration observed, because during 
endochondral ossification bone regeneration is preceded by 
osteoclast-mediated degradation of the cartilage template. 
Osteoclasts are monocyte-derived cells. Furthermore, 
chondrogenically differentiated MSC pellets that were 
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exposed to IL-1, a pro-inflammatory cytokine, showed 
enhanced accumulation of MMP-13 and increase levels of 
released stromal cell-derived factor-1, which resulted in 
more osteoclast recruitment and faster bone regeneration 
(Scotti et al., 2013).
 Obtaining high yields of MSCs is important for 
generating sufficient chondrogenically differentiated MSC 
pellets to be used in clinical applications. MSCs that are 
capable of undergoing chondrogenic differentiation can 
be obtained from various tissues including bone marrow, 
fat, muscle, synovium, periosteum (Sakaguchi et al., 
2005). Bone marrow derived MSCs, used here, have more 
chondrogenic potential than fat derived MSCs (Winter 
et al., 2003) or muscle derived MSCs (Sakaguchi et al., 
2005). Bone marrow derived MSC can be obtained by a 
simple percutaneous procedure, and the yield of MSCs 
obtained can be improved when a concentration device 
is used that centrifuges a larger volume of bone marrow 
(Hernigou et al., 2005). Furthermore, the proliferation 
of obtained MSC can be enhanced by supplementing in 
vitro culture media with FGF-2, or other factors such as 
platelet-derived growth factor, ascorbic acid and epidermal 
growth factor (Gharibi and Hughes, 2012). More MSCs 
result in a higher volume of chondrogenically differentiated 
MSC pellets that can be generated. But with the culturing 
protocol that we used here, we were able to generate around 
200 chondrogenically differentiated MSC pellets per donor. 
Theoretically this can result in 2.7 cm3 pellet volume, and 
is similar to volumes in which commercially available bone 
substitutes are sold (Van der Stok et al., 2013c). Although 
this volume may not be sufficient or requires the use of 
additional bone substitutes to graft large bone defects 
in humans (> 2 cm), it might already be enough to graft 
the much smaller fracture gap that is typically seen in an 
atrophic non-unions (< 2 mm) (Naimark et al., 1981).
 VEGF is known to play a key role in endochondral 
ossification (Patil et al., 2012) and the release of VEGF 
could also be to the driving factor through which 
chondrogenically differentiated MSC pellets can initiate 
endochondral ossification. VEGF was indeed produced and 
released by chondrogenically differentiated MSC pellets 
of all three donors (Fig. 11), but endochondral ossification 
did not occur after grafting with chondrogenically 
differentiated MCS pellets of donor 2 (Fig. 5). The 
release of VEGF from chondrogenically differentiated 
MSC pellets was also less than from undifferentiated 
MSC pellets at the moment of implantation (Fig. 11). The 
cumulative release of VEGF from the chondrogenically 
differentiated MSC pellets, however, might still be 
superior after in vivo implantation due to prolonged cell 
survival in low-oxygen environment of the hypertrophic 
chondrocytes. But the CD34 immunostaining performed 
on grafted defects after 7 and 14 (Figs. 6 and 7) and 
after 8 weeks (Fig. 9) did not suggest that a lot of vessel-
forming activity was taking place around chondrogenically 
differentiated MSC pellets. Vessel formation, however, 
may have been more controlled and synchronised with the 
bone formation compared to vessel formation upon grafting 
with undifferentiated pellets. This possible spatiotemporal 
role of VEGF in endochondral ossification upon grafting 
with chondrogenically differentiated MSC pellets warrants 
further investigation in longitudinal in vivo setting.
 Bone regeneration was after grafting bone defects with 
chondrogenically differentiated MSC pellets was donor-
depend (Fig. 5), and this has also been observed after 
subcutaneous implantation (Farrell et al., 2009; Farrell et 
al., 2011). The non-potent chondrogenically differentiated 
MSC pellets of donor 2 did contain hypertrophic 
chondrocytes that produced VEGF, similar as the potent 
chondrogenically differentiated MSC pellets of donor 1 
and 3 (Fig. 8) and there was no clear difference in the 
release of angiogenic cytokines between the donors (Fig. 
11). The only difference between the non-potent and the 
potent chondrogenically differentiated MSC pellets that 
we could find was their size (Fig. 8), non-potent pellets 
were smaller and contained less extracellular matrix. This 
may indicate an important role for the extracellular matrix 
that is generated by chondrogenically differentiated MSC 
pellets, but on the other hand it has also been suggested 
that hypertrophic chondrocytes undergoes a transformation 
into bone (Scotti et al., 2010; Farrell et al., 2011; Bahney 
et al., 2013;). Determining the exact composition of 
the extracellular matrix generated by chondrogenically 
differentiated MSC pellets of a larger number of 
different donors followed by an in vivo implantation 
to assess their potency to form bone and to determine 
the survival of these hypertrophic chondrocytes in vivo 
may provide valuable new insights in the mechanism 
through with chondrogenically differentiated MSCs 
initiate endochondral ossification and may help to develop 
protocols to generate potent pellets of each donor.
Conclusion
In conclusion, grafting critical femoral bone defects 
that were left empty to establish an atrophic non-union 
with chondrogenically differentiated MSC pellets leads 
to significantly more bone regeneration than grafting 
with undifferentiated MSC pellets in athymic rats. With 
chondrogenically differentiated MSC pellets, bone 
regenerates rapidly through endochondral ossification, 
and through bone remodelling leading to restoration of 
the cortex and the intramedullary space. When this MSC-
based approach can be optimised such that sufficient 
and potent chondrogenically differentiated MSC pellets 
can be generated for each single patient, grafting with 
chondrogenically differentiated MSC pellets may become 
a successful clinical treatment for bone repair in atrophic 
non-unions and large bone defects.
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Discussion with Reviewers
I. Martin: No empty control was incorporated into the 
study. Why was this? Figure 1 indicates that a certain 
amount of spontaneous repair had occurred during the 
initial 6 weeks. Do the authors know if bridging would 
occur if these defects are left untreated for 14 weeks (6+8 
weeks)? Is there data from this or earlier studies from 
your lab using this model to confirm this is a critical sized 
defect?
Authors: The critical size of this bone defect using this 
fixation method has been confirmed by our group in two 
published studies (Chatterjea et al., 2013; van der Stok 
et al., 2013a, text references). In these studies, untreated 
defects did not show spontaneous bridging up to 12 weeks. 
Furthermore, in an unpublished study (Koolen et al., in 
preparation) we have also included an empty control group 
that was followed for 16 weeks. No spontaneous bridging 
was observed.
 An empty control group was not included since our 
primary aim was to determine the regenerative capacity of 
chondrogenic differentiated MSCs in an established defect. 
The 6 mm defect was left untreated for 6 weeks. There was 
only little bone formation and after this period the defect 
is filled with fibrous tissue. The best control to address our 
primary research question is putting undifferentiated MSCs 
in the defect. To make this feasible without using scaffolds 
a three-day incubation was needed so that transplantable 
pellets were formed. Having empty controls in this 
established non-union model, would not provide further 
data with regard to our research question. The little bone 
formation that is indeed notable, but in regard to the ch-
MSC pellets it is very minor. Previous studies did examine 
the effects of undifferentiated and osteogenic differentiated 
MSCs. This strategy has little success, please see Steinert 
et al. (2012) (text reference). This is the primary reason to 
examine new strategies.
I. Martin: What was the logic for implanting 6 pellets 
per defect?
Authors: We were able to completely fill the defect using 
6 pellets, this is shown in Fig. 1. Although you only can 
see 5 pellets, the defect was nicely filled.
I. Martin: Was the repair 6 weeks after implantation of 
ud-MSCs worse than that at the start of the study (i.e., 6 
weeks after the defect was originally created)? Comparing 
Fig. 3 to Fig. 1 might suggest it is.
Authors: Indeed the reader might get this the impression 
when only looking at Figs.1 and 3, but when you also 
take the micro-CT scans of Fig. 5a into account, one can 
also observe fairly good bone regeneration 8 weeks after 
implantation of ud-MSCs. So we think it is more or less 
equal.
I. Martin Other studies that incorporate undifferentiated 
MSCs into a ceramic scaffold or similar have demonstrated 
the utility of this approach. Could the absence of a 
supporting scaffold (and the cues it provides to MSCs) be 
the reason for the poor repair observed with ud-MSCs? This 
is an important question, as having to chondrogenically 
prime MSCs for 3 weeks prior to implantation is obviously 
an additional hurdle to be overcome for clinical translation.
Authors: The absence of a supporting scaffold is likely 
to have a negative effect on ud-MSC pellets, but this is 
also true for the ch-MSC pellets. Using a suitable scaffold 
for additional mechanical support with ch-MSC pellets 
may help to avoid the formation of hypertrophic non-
union. To design scaffolds such that, next to providing 
mechanical support, they also provide clues to the MSCs 
is very interesting. Based on our results, we then suggest 
providing clues that stimulate chondrogenic differentiation 
of MSCs, because this can initiate bone regeneration 
through endochondral ossification and that appears to be 
very fast and efficient.
